Immune checkpoint inhibitors (ICIs) exert antitumor effects by inducing the immune response to tumor cells; however, this also leads to an increased incidence of immune-related adverse events (irAEs). Enteritis is the most common irAE caused by anti-CTLA-4 antibodies, and its frequency and pathophysiology vary based on the combination of ICIs and other antitumor drugs (cell-mediated anticancer or molecular target drugs). Enteritis is therefore considered an irAE that requires special attention. The following section outlines the recent findings.
|Translated title of the contribution
|ENDOSCOPIC FINDINGS AND MANAGEMENTS OF IMMUNE CHECKPOINT INHIBITOR-RELATED GASTROINTESTINAL DISORDER
|Number of pages
|Published - 2022 May
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging